

# Phagocytic cells metabolize 25-hydroxyvitamin D<sub>3</sub> to 10-oxo-19-nor-25-hydroxyvitamin D<sub>3</sub> and a new metabolite, 8 $\alpha$ ,25-dihydroxy-9,10-seco-4,6,10(19)-cholestatrien-3-one

Takamune Hayashi, Sachiko Yamada\*, Chisato Miyaura, Hirofumi Tanaka, Keiko Yamamoto\*, Etsuko Abe, Hiroaki Takayama\* and Tatsuo Suda

*Department of Biochemistry, School of Dentistry, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142 and*

*\*Faculty of Pharmaceutical Sciences, Teikyo University, Sagamiko, Kanagawa 199-01, Japan*

Received 23 April 1987

The metabolism of 25-hydroxyvitamin D<sub>3</sub> [25(OH)D<sub>3</sub>] was examined in several phagocytic cells including alveolar macrophages and myeloid leukemia cells (M1, HL-60 and U937). Phagocytic cells converted 25(OH)D<sub>3</sub> to 10-oxo-19-nor-25-hydroxyvitamin D<sub>3</sub> and a new metabolite. The former metabolite was dominant in shorter incubation periods (1 h), whereas the latter dominated over longer incubation periods (24 h). The new metabolite was produced from 25(OH)D<sub>3</sub> directly but not through 10-oxo-19-nor-25-hydroxyvitamin D<sub>3</sub>. The new metabolite was unequivocally identified as 8 $\alpha$ ,25-dihydroxy-9,10-seco-4,6,10(19)-cholestatrien-3-one. These results suggest that phagocytic cells somehow promote oxidation of the triene part of vitamin D compounds.

Vitamin D metabolism; Phagocytic cell; Macrophage; 10-Oxo-19-nor-25-hydroxyvitamin D<sub>3</sub>; 8 $\alpha$ ,25-Dihydroxy-9,10-seco-4,6,10(19)-cholestatrien-3-one

## 1. INTRODUCTION

Recently, much attention has been focused on the metabolism of vitamin D<sub>3</sub> in phagocytic cells. Phagocytic cells such as human blood leukocytes [1], monocytes [2] and tissue macrophages [1–3], and their transformed cells (HL-60 and U937) [4–7] have been reported to metabolize 25-hydroxyvitamin D<sub>3</sub> [25(OH)D<sub>3</sub>] to more polar metabolites including 10-oxo-19-nor-25-hydroxyvitamin D<sub>3</sub> [10-oxo-19-nor-25(OH)D<sub>3</sub>]. This metabolite has two isomers, 5*E* and 5*Z* forms. The former structure is similar to that of 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> [1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>], the active form of vitamin D<sub>3</sub>, because the 3 $\beta$ -hydroxyl function of (5*E*)-10-oxo-19-nor-25(OH)D<sub>3</sub> occupies the posi-

tion of the 1 $\alpha$ -hydroxyl function of 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>. These results led us to consider that the 5*E* form of 10-oxo-19-nor-25(OH)D<sub>3</sub> might be responsible for inducing monocytic differentiation. It has also been pointed out that this metabolite migrates at a similar position to 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> in a straight-phase high-pressure liquid chromatography (HPLC) system using 10% 2-propanol in hexane, the traditional chromatographic system for separating 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>. However, neither the role nor the regulation of its production has been established.

In the course of investigating the metabolism of 25(OH)D<sub>3</sub> in phagocytic cells, we found a new metabolite of 25(OH)D<sub>3</sub> which migrated at a similar position to 24*R*,25-dihydroxyvitamin D<sub>3</sub> [24*R*,25(OH)<sub>2</sub>D<sub>3</sub>] in four different HPLC systems. The metabolite has now been identified as 8 $\alpha$ ,25-dihydroxy-9,10-seco-4,6,10(19)-cholestatrien-3-one. Here, we examined the relationship be-

Correspondence address: T. Suda, Department of Biochemistry, School of Dentistry, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142, Japan

tween the production of the two metabolites, 10-oxo-19-nor-25(OH)D<sub>3</sub> and the new metabolite, in phagocytic cells.

## 2. MATERIALS AND METHODS

### 2.1. Animals and drugs

Male mice, 6–8-week-old ddy strain, were obtained from Shizuoka Laboratory Animal Center (Shizuoka). 25(OH)D<sub>3</sub>, 1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub> and 24R,25(OH)<sub>2</sub>D<sub>3</sub> were kindly donated by Dr I. Matsunaga (Chugai Pharmaceutical Co., Tokyo). (5E)- and (5Z)-10-oxo-19-nor-25(OH)D<sub>3</sub> and 25,26S-dihydroxyvitamin D<sub>3</sub> [25,26S(OH)<sub>2</sub>D<sub>3</sub>] were synthesized in our laboratory. 25(OH)-[26,27-<sup>3</sup>H]D<sub>3</sub> (spec. act. 20.6 Ci/mmol) was obtained from Amersham (England).

### 2.2. Cells

Alveolar macrophages were collected by the tracheobronchial lavage method and purified as reported in [8]. The murine myeloid leukemia cell line (M1, clone T22) was kindly donated by Dr M. Hozumi (Saitama Cancer Center Research Institute, Saitama). The human promyelocytic leukemia cell line (HL-60) was provided by Dr H. Hemmi (Tohoku University, Sendai). The human monoblast-like lymphoma cell line (U937) was provided by Dr K. Takeda (Showa University, Tokyo).

### 2.3. Incubations of phagocytic cells with 25(OH)[<sup>3</sup>H]D<sub>3</sub>

Phagocytic cells ( $7 \times 10^6$ ) were incubated with 1  $\mu$ Ci 25(OH)[<sup>3</sup>H]D<sub>3</sub> in 3.5 ml of a serum-free medium for 1–36 h at 37°C under 5% CO<sub>2</sub>-95% air. The serum-free medium consisted of a mixture of RPMI 1640, Dulbecco's modified Eagle's MEM and Ham's F-12 (Gibco, Grand Island, NY) (2:1:1) containing 2.219 mg/ml of sodium bicarbonate, 100  $\mu$ g/ml of streptomycin sulfate, 100 U/ml of penicillin G potassium, 8.47 ng/ml of selenous acid, 110  $\mu$ g/ml of sodium pyruvate and 1  $\mu$ g/ml of human transferrin (Sigma, St. Louis, MO). After incubation, the cells and medium were extracted together [9], and the samples were applied to a preparative silica Sep-Pak cartridge column (Waters, Milford, MA) [10]. The fraction containing dihydroxy metabolites of vitamin D<sub>3</sub> was subjected to Waters HPLC, pump model

6000 A, equipped with a Finepak Sil column (0.46  $\times$  25 cm, Jasco, Tokyo). The column was eluted with 10% 2-propanol in hexane at a flow rate of 1 ml/min. Fractions were collected every 30 s and the radioactivity of the eluate was measured with a liquid scintillation counter.

## 3. RESULTS

Alveolar macrophages incubated for 1 h with 25(OH)[<sup>3</sup>H]D<sub>3</sub> produced 10-oxo-19-nor-25(OH)D<sub>3</sub> as a mixture of 5E and 5Z isomers (fig.1A). The natural 5E isomer was accompanied by the 5Z isomer photochemically produced, because a special precaution was not taken to avoid exposure




Fig.1. HPLC profiles of the metabolites of 25(OH)[<sup>3</sup>H]D<sub>3</sub> produced by alveolar macrophages incubated with 25(OH)[<sup>3</sup>H]D<sub>3</sub> for 1 h (A) and 24 h (B). Lipid extracts of the incubation mixture were first subjected to a silica Sep-Pak cartridge column. A radioactive fraction eluted with 60% ethyl acetate in *n*-hexane was applied to HPLC (Finepak Sil column, 0.46  $\times$  25 cm, 10% 2-propanol in hexane, 1 ml/min, monitored at 265 nm). Arrows show the elution positions of the authentic vitamin D<sub>3</sub> compounds.

of the experimental vessels to room light during incubation and chromatographic separation. The production of the metabolite attained a maximum at 1 h and decreased thereafter (fig.2A). Formation of 10-oxo-19-nor-25(OH)D<sub>3</sub> was also observed when 25(OH)D<sub>3</sub> was allowed to stand for 1–72 h at 37°C under 5% CO<sub>2</sub>-95% air in the medium without the cells (fig.2B). Formation of the metabolite in the medium alone increased time-dependently and attained a plateau at 48 h. The structures of (5*E*)- and (5*Z*)-10-oxo-19-nor-25(OH)D<sub>3</sub> were confirmed by ultraviolet (maximum at 310 nm), mass spectra [402(M<sup>+</sup>), 384, 369, 359, 273 and 177], and chemical synthesis.

When alveolar macrophages were incubated with 25(OH)[<sup>3</sup>H]D<sub>3</sub> for a longer time, another radioactive peak appeared at approx. 17 min (fig.1B). The production of the new metabolite increased time-dependently and reached a maximum at 12–24 h (fig.2A). This metabolite was not produced when 25(OH)D<sub>3</sub> was allowed to stand at 37°C in the medium without the cells.

The elution position of the new metabolite was




Fig.2. Time course of the change in the rate of conversion of 25(OH)D<sub>3</sub> to 10-oxo-19-nor-25(OH)D<sub>3</sub> (—) and the new metabolite (---). Alveolar macrophages were incubated with 25(OH)[<sup>3</sup>H]D<sub>3</sub> for 1–36 h (A). 25(OH)[<sup>3</sup>H]D<sub>3</sub> was allowed to stand in medium without macrophages for 1–72 h (B). Points and bars represent means  $\pm$  SE of 3–6 independent sets of experiments.




Fig.3. Cochromatography of the new metabolite with authentic vitamin D<sub>3</sub> compounds on three different HPLC systems. The radioactive peak eluting at 17 min on the HPLC system shown in fig.1B was pooled and cochromatographed with authentic vitamin D<sub>3</sub> compounds on three different HPLC systems: (i) Lichrosorb Si 60 column (0.46  $\times$  25 cm), 2% methanol in dichloromethane, 1 ml/min (A); (ii) same column as in (i), hexane/dichloromethane/methanol (16:2:1), 1 ml/min (B); (iii) Finepak Sil C<sub>18</sub> column (0.46  $\times$  25 cm), 15% water in methanol, 1 ml/min (C). The solid line shows the absorbance at 270 nm and the bar represents radioactivity in each 1-min fraction. Arrows show the elution positions of the authentic compounds indicated.

compared with those of authentic vitamin D compounds in three different HPLC systems besides the one shown in fig.1: a straight-phase column with methanol-dichloromethane (fig.3A) and that with hexane-dichloromethane-methanol solvent systems (fig.3B), and a reverse-phase column with water-methanol (fig.3C). The new metabolite was eluted in the vicinity of  $24R,25(OH)_2D_3$  in these three HPLC systems, but did not comigrate to the same position of  $24R,25(OH)_2D_3$ .

The time course of the production of the two metabolites (fig.2A) led us to examine the possibility that the new metabolite is derived from 10-oxo-19-nor-25(OH) $D_3$ . 10-Oxo-19-nor-25(OH)-[ $^3H$ ] $D_3$  was synthesized by allowing 25(OH)[ $^3H$ ] $D_3$  to stand for 2 days at 37°C in the medium alone. When incubated with alveolar macrophages, 10-oxo-19-nor-25(OH)[ $^3H$ ] $D_3$  was not converted to the new metabolite at any incubation times (not shown).

Metabolism of 25(OH) $D_3$  was also studied in several lines of mouse and human myeloid leukemia cells (M1, U937, and HL-60). All of these myeloid cells produced the two metabolites, 10-oxo-19-nor-25(OH) $D_3$  and the new metabolite. The mode of production of the two metabolites by these cells was similar to that by alveolar




Fig.4. Conversion of 25(OH) $D_3$  to 10-oxo-19-nor-25(OH) $D_3$  (A) and the new metabolite (B). Phagocytic cells ( $7 \times 10^6$ ) (alveolar macrophages, M1, U937, and HL-60) were incubated with 1  $\mu$ Ci 25(OH)[ $^3H$ ] $D_3$  for 1 h (empty columns) or 24 h (hatched columns). Columns and bars represent means  $\pm$  SE of 3-4 independent sets of experiments.




Fig.5. The structure of the new metabolite, 8 $\alpha$ ,25-dihydroxy-9,10-seco-4,6,10(19)-cholestatrien-3-one.

macrophages; 10-oxo-19-nor-25(OH) $D_3$  was the dominant metabolite at 1 h, while the new metabolite was the major metabolite at 24 h (fig.4).

The new metabolite was isolated by incubating 25(OH) $D_3$  with M1 cells and unequivocally identified as 8 $\alpha$ ,25-dihydroxy-9,10-seco-4,6,10(19)-cholestatrien-3-one (fig.5) on the basis of its ultraviolet (maximum at 295 nm and minimum at 245 nm), infrared (presence of a conjugated carbonyl group at 1660  $cm^{-1}$ ), mass ( $M^+$ : 414  $m/e$ ), and  $^1H$ -NMR spectra. The stereochemistry of the hydroxyl group newly introduced into the 8-position was determined to be  $\alpha$  by chemical synthesis. Details of the identification work have been submitted.

#### 4. DISCUSSION

We found that the conversion of 25(OH) $D_3$  to 10-oxo-19-nor-25(OH) $D_3$  occurred in the presence and absence of phagocytic cells. The time course of the conversion of 25(OH) $D_3$  to 10-oxo-19-nor-25(OH) $D_3$  was, however, different between the presence and absence of alveolar macrophages. Formation of the metabolite attained a maximum at 1 h and decreased thereafter in the presence of macrophages, whereas it increased time-dependently in the absence of the cells. The rate of conversion of 25(OH) $D_3$  to the metabolite was much higher in the absence of macrophages. Using solubilized kidney mitochondria, Brown and DeLuca [11] have also reported that 10-oxo-19-nor-25(OH) $D_3$  is produced when 25(OH) $D_3$  is allowed to stand in a buffer alone and also in a reconstitution system without the P-450 fraction, but that its formation is suppressed by the addition of antioxidants. From these results they suggested that the production of 10-oxo-19-nor-25(OH) $D_3$  occurs via a mechanism involving peroxidation.

Our preliminary experiments have also indicated that the addition of divalent iron ( $\text{Fe}^{2+}$ ) with oxygen gas causes the conversion of  $25(\text{OH})\text{D}_3$  to  $(5E)$ -10-oxo-19-nor- $25(\text{OH})\text{D}_3$  in the absence of phagocytic cells (unpublished). Phagocytic cells, however, somehow enhance this oxidation. These results confirm the suggestion of Brown and DeLuca [11].

Longer incubations (12–36 h) of phagocytic cells with  $25(\text{OH})[^3\text{H}]\text{D}_3$  produced another metabolite eluting at 17 min on HPLC. The new metabolite was unequivocally identified as  $8\alpha,25$ -dihydroxy-9,10-seco-4,6,10(19)-cholesta-trien-3-one. In contrast to the production of 10-oxo-19-nor- $25(\text{OH})\text{D}_3$ , the new metabolite was formed only in the presence of phagocytic cells. In addition, the new metabolite was not produced when phagocytic cells were incubated with radioactive 10-oxo-19-nor- $25(\text{OH})\text{D}_3$ , suggesting that the new metabolite is formed from  $25(\text{OH})\text{D}_3$  directly.

It is interesting that the new metabolite migrated in the vicinity of authentic  $24R,25(\text{OH})_2\text{D}_3$  in the four different HPLC systems (figs 1,3). During the preparation of the present manuscript, Reichel et al. [12] reported that HL-60 cells exposed to  $1\alpha,25(\text{OH})_2\text{D}_3$  produced  $24,25(\text{OH})_2\text{D}_3$  from  $25(\text{OH})\text{D}_3$ . In our study, phagocytic cells were not exposed to  $1\alpha,25(\text{OH})_2\text{D}_3$  before incubation with  $25(\text{OH})[^3\text{H}]\text{D}_3$ , and the production of  $24,25(\text{OH})_2[^3\text{H}]\text{D}_3$  was not observed. It is also interesting that Reichel et al. [12] did not find the new metabolite under their experimental conditions. Further studies are needed to define the relationship between the formation of  $24,25(\text{OH})_2\text{D}_3$  and the new metabolite described here.

A recent report has indicated that  $25(\text{OH})\text{D}_3$  is metabolized to  $1\alpha,25(\text{OH})_2\text{D}_3$  in human alveolar macrophages treated in vitro with interferon- $\gamma$  [13]. In this study, we isolated the two metabolites oxidized at the triene part, 10-oxo-19-nor- $25(\text{OH})\text{D}_3$  and  $8\alpha,25$ -dihydroxy-9,10-seco-4,6,10(19)-cholestatrien-3-one. In the classical metabolism of vitamin  $\text{D}_3$ , the non-triene part was oxidized at the  $1\alpha$ , 24-, 25- and 26-positions. It is important to clarify the mechanism underlying the

differences of these two types of oxidation. The biological significance of the new metabolite must also be elucidated in the future.

## ACKNOWLEDGEMENTS

This work was supported by Grants-In-Aid (6044086 and 61570894) from the Ministry of Science, Education and Culture of Japan.

## REFERENCES

- [1] Cohen, M.S. and Gray, T.K. (1984) *Proc. Natl. Acad. Sci. USA* 81, 931–934.
- [2] Gray, T.K., Maddux, F.W., Lester, G.E. and Williams, M.E. (1982) *Biochem. Biophys. Res. Commun.* 109, 723–729.
- [3] Okabe, T., Ishizuka, S., Fujisawa, M., Watanabe, J. and Takaku, F. (1984) *Biochem. Biophys. Res. Commun.* 123, 822–830.
- [4] Okabe, T., Ishizuka, S., Fujisawa, M., Watanabe, J. and Takaku, F. (1985) *Biochem. Biophys. Res. Commun.* 127, 635–641.
- [5] Bar-Shavit, Z., Horst, R.L., Chappel, J.C., Ross, F.P., Gray, R.W. and Teitelbaum, S.L. (1986) *Calcif. Tissue Int.* 39, 328–333.
- [6] Gray, T.K., Millington, D.S., Maltby, D.A., Williams, M.E., Cohen, M.S. and Dodd, R.C. (1985) *Proc. Natl. Acad. Sci. USA* 82, 8218–8221.
- [7] Ishizuka, S., Matsui, T., Nakao, Y., Fujita, T., Okabe, T., Fujisawa, M., Watanabe, J., Takaku, F., Bishop, J.E., Reichel, H. and Norman, A.W. (1986) *Eur. J. Biochem.* 161, 233–239.
- [8] Sone, S., Bucana, C., Hoyer, L.C. and Fidler, I.J. (1981) *Am. J. Pathol.* 103, 234–346.
- [9] Mallon, J.P., Hamilton, J.G., Nauss-Karol, C., Karol, R.J., Ashley, C.J., Matuszewski, D.S., Tratnyek, C.A., Bryce, G.F. and Miller, O.N. (1980) *Arch. Biochem. Biophys.* 201, 277–285.
- [10] Adams, J.S., Clemens, T.L. and Holick, M.F. (1981) *J. Chromatogr.* 226, 198–201.
- [11] Brown, A. and DeLuca, H.F. (1985) *J. Biol. Chem.* 260, 14132–14136.
- [12] Reichel, H., Koeffler, H.P. and Norman, A.W. (1986) *Arch. Biochem. Biophys.* 251, 222–231.
- [13] Koeffler, H.P., Reichel, H., Bishop, J.E. and Norman, A.W. (1985) *Biochem. Biophys. Res. Commun.* 127, 596–603.